BNP/CALL/EDWARDS LIFESCIENCES/110/0.1/17.01.25 | Market Closed - Boerse Frankfurt Warrants 15:50:30 2024-05-16 EDT | ||
| 0.3 EUR | +3.45% |
|
| Current month | +42.86% | ||
| 1 month | -28.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-16 | 0.3 | +3.45% |
| 24-05-15 | 0.29 | +38.10% |
| 24-05-14 | 0.21 | +10.53% |
| 24-05-13 | 0.19 | -13.64% |
| 24-05-10 | 0.22 | -8.33% |
Real-time Boerse Frankfurt Warrants
Last update May 16, 2024 at 03:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PN3Y13 |
| ISIN | DE000PN3Y134 |
| Date issued | 2023-05-25 |
| Strike | 110 $ |
| Maturity | 2025-01-17 (246 Days) |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.01 € |
|---|---|
| Lowest since issue | 0.07 € |
| Spread | 0.01 € |
| Spread % | 3.23% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.11
USD
Average target price
95.9
USD
Spread / Average Target
+6.43%
- Stock Market
- Warrants
- Warrant